Tumour markers are poor predictors for relapse or progression in neuroblastoma

被引:57
作者
Simon, T
Hero, B
Hunneman, DH
Berthold, F
机构
[1] Univ Cologne, Childrens Hosp, Dept Pediat Haematol & Oncol, D-50924 Cologne, Germany
[2] Univ Gottingen, Childrens Hosp, D-3400 Gottingen, Germany
关键词
neuroblastoma; relapse; tumour markers; vanillylmandelic acid; homovanillic acid; neurone-specific enolase; lactate dehydrogenase; follow-up;
D O I
10.1016/S0959-8049(03)00376-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The value of the tumour markers vanillylmandelic acid (VMA) and homovanillic acid (HVA) in urine (u) and serum (s), neurone-specific enolase (NSE). and lactate dehydrogenase (LDH) in the early prediction of relapse/progression in neuroblastoma is not known. We analysed the data of neuroblastoma patients who had successfully completed first-line treatment and had laboratory results available from their initial diagnosis and from relapse/progression (n = 196). Patients' overall survival from relapse or progression was 21.5 +/- 4.2% (mean standard deviation). At diagnosis, we found abnormal results in 75% for VMA and/or HVA (s), 92% for VMA and/or HVA (u), 90% for NSE, and 81% for LDH. We found a lower incidence of abnormal results at relapse or progression,with 40% for VMA and/or HVA (s), 54% for HVA and/or VMA (u), 61% for NSE, and 48% for LDH. Sensitivity of markers was higher for metastatic compared with local recurrence. NSE was the best, being able to detect 42% of the localised relapses. 77% of the combined local/metastatic relapses, and 69% of the metastatic recurrences. Relapse or progression in neuroblastoma cannot be detected reliably by monitoring tumour markers alone. Therefore, follow-up of neuroblastoma patients must include clinical assessment and imaging studies. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1899 / 1903
页数:5
相关论文
共 14 条
[1]   Neuroblastoma - Current drug therapy recommendations as part of the total treatment approach [J].
Berthold, F ;
Hero, B .
DRUGS, 2000, 59 (06) :1261-1277
[2]  
BERTHOLD F, 1991, In Vivo (Attiki), V5, P245
[3]   SERUM VANILLYLMANDELIC ACID HOMOVANILLIC-ACID CONTRIBUTES TO PROGNOSIS ESTIMATION IN PATIENTS WITH LOCALIZED BUT NOT WITH METASTATIC NEUROBLASTOMA [J].
BERTHOLD, F ;
HUNNEMAN, DH ;
HARMS, D ;
KASER, H ;
ZIESCHANG, J .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (12) :1950-1954
[4]  
BERTHOLD F, 1997, KOMPENDIUM INTERNIST, P1805
[5]   CLINICAL SIGNIFICANCE OF CATECHOLAMINE EXCRETION LEVELS IN DIAGNOSIS AND TREATMENT OF NEUROBLASTOMA [J].
BOND, JV .
ARCHIVES OF DISEASE IN CHILDHOOD, 1975, 50 (09) :691-695
[6]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[7]   INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[8]  
Hero B, 2001, MED PEDIATR ONCOL, V36, P220, DOI 10.1002/1096-911X(20010101)36:1<220::AID-MPO1053>3.0.CO
[9]  
2-6
[10]   MASS FRAGMENTOGRAPHIC DETERMINATION OF HOMOVANILLIC AND 4-HYDROXY-3-METHOXY MANDELIC-ACIDS IN 50 MU-L PLASMA [J].
HUNNEMAN, DH .
CLINICA CHIMICA ACTA, 1983, 135 (02) :169-174